(Q51249793)

2 April 2018

title

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases. (English)

1 reference

2 April 2018

diffuse large B-cell lymphoma

main subject

Burkitt lymphoma

0 references

1 reference

8

Wing C Chan

1 reference

2 April 2018

James O Armitage

14

James O Armitage

1 reference

2 April 2018

Julie M Vose

13

Julie M Vose

1 reference

2 April 2018

Dennis D Weisenburger

15

Dennis D Weisenburger

1 reference

2 April 2018

David Crockett

2

David Crockett

1 reference

2 April 2018

Bhavana J. Dave

3

Bhavana J Dave

1 reference

2 April 2018

Timothy Greiner

10

Timothy C Greiner

1 reference

2 April 2018

Anamarija M Perry

1

Anamarija M Perry

1 reference

2 April 2018

Patricia Aoun

7

Patricia Aoun

1 reference

2 April 2018

Phillip J Bierman

11

Phillip Bierman

1 reference

2 April 2018

Robert Gregory Bociek

12

Robert Gregory Bociek

1 reference

2 April 2018

author name string

Pamela Althof

4

1 reference

2 April 2018

Lisa Winkler

5

1 reference

2 April 2018

Lynette M Smith

6

1 reference

2 April 2018

Kai Fu

9

1 reference

2 April 2018

language of work or name

English

0 references

publication date

18 April 2013

1 reference

2 April 2018

British Journal of Haematology

published in

1 reference

2 April 2018

volume

162

1 reference

2 April 2018

issue

1

1 reference

2 April 2018

page(s)

40-49

1 reference

2 April 2018

Double-hit B-cell lymphomas

cites work

1 reference

B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology.

21 January 2018

1 reference

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

21 January 2018

1 reference

Molecular diagnosis of Burkitt's lymphoma

21 January 2018

1 reference

21 January 2018

Lymphoma cytogenetics

1 reference

High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma.

21 January 2018

1 reference

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

21 January 2018

1 reference

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

Commentary on the WHO classification of tumors of lymphoid tissues (2008): "Gray zone" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma.

21 January 2018

1 reference

Grey zone lymphomas: lymphomas with intermediate features

21 January 2018

1 reference

Unbiased Recursive Partitioning: A Conditional Inference Framework

21 January 2018

1 reference

A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

21 January 2018

1 reference

BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma

21 January 2018

1 reference

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

21 January 2018

1 reference

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

21 January 2018

1 reference

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

21 January 2018

1 reference

Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma

21 January 2018

1 reference

Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.

21 January 2018

1 reference

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab

21 January 2018

1 reference

Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis

21 January 2018

1 reference

The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective

21 January 2018

1 reference

MYC and aggressive B-cell lymphomas

21 January 2018

1 reference

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma

21 January 2018

1 reference

Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas.

21 January 2018

1 reference

Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations

21 January 2018

1 reference

The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12343

1 reference

2 April 2018

1 reference

2 April 2018